DSpace eaPSMU :: Browsing by Автор "Gusachenko, I."

Перегляд за Автор "Gusachenko, I."

Зараз показуємо 1 - 8 з 8

Efficacy profile daily injection filgrastim in chemotherapy-induced (ct) febrile neutropenia (fn) in patients with acute leukemia (al): ukranian retrospective study in a real-life cohort
(Clinical Limphoma, Myeloma & Leukemia, 2024-09-01) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Gusachenko, I.; Лиманець, Тетяна Володимирівна; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна; Гусаченко, Юлія володимирівна
Materials and methods: 59 primary patients with AL (median age: 53.8, range: 9.23 years; male 35 (59.3%), female 24 (40.7%); ECOG I-II) were included in the study during 2021-2023 and received the standard induction CT according to ESMO Clinical Practice Guidelines in our department. The patients were enrolled into two groups: 31(52.5%) and 28(47.5%) pts in control and study to Filgrastim groups, respectively. 21(35.6%) acute myeloid leukemia (AML) pts and 10(17%) acute lymphoblastic leukemia (ALL) pts were involved in IA and IIA control groups; 17(28.8%) AML-pts and 11(18.6%) ALL-pts were contained in IB and IIB study groups, respectively. Results. We verified Gr 4 neutropenia in 17(80.95%) pts of group IA and 14 (82.35%) pts of group IB which received regimen 7+3 with/without etoposide. Duration time of Gr 4 neutropenia in group IB versus group IA was 1.5 times less, t(38)= 3.65, р˂0.001. FN developed significantly rarer in IB group with G-CSFs, X2(1, N=38) = 4.87, p˂0.03. Among the patients with ALL was registered Gr 4 neutropenia in 6 (60%) pts of group IIA and 6 (54.5%) pts of group IIB. Duration time of FN was 2.7 times less in IIB group with G-CSFs than in group IIA, t(21)= 6.62, р˂0.00001. But there was no difference in the number of FN episodes developed in IIB vs IIA groups, p˃0.05. Conclusions. Filgrastim effectively prevents the development of FN in patients with AML against the background of severe cytostatic neutropenia. Thus, the use of Filgrastim made it possible to reduce the duration of severe neutropenia in patients with AL during induction CT.
Joint analysis of 1695 cases of malignant lymphoma from the ukranian and cluj napoca lymphoma registries
(Wiley, 2025-06) Shokun, N.; Tomuleasa, C.; Shapovalenko, N.; Stepanishyna, Y.; Gusachenko, I.; Lymanets, T.; Zdrenghea, M.; Conte, L.; Fetica, B.; Skrypets, T.; Moiseienko, K.; Lukavetskyy, L.; Viktor, K.; Leonova, I.; Martina, Z.; Tytorenko, I.; Kadnikova, T.; Federico, M.; Kryachok, I.; Лиманець, Тетяна Володимирівна
Background: Lymphomas represent a diverse group of hematologic malignancies with substantial regional variations in incidence, histological subtypes, and disease presentation. Cancer registries serve as essential tools for understanding epidemiological trends, guiding clinical decision‐making, and improving patient outcomes. This study integrates data from the Ukrainian and Cluj Napoca Lymphoma registries to analyze demographic characteristics, histological distribution, and disease presentation across different populations. Aim: The objective of this study was to perform a comparative analysis of malignant lymphoma cases across different regions, identifying trends in histopathology, disease stage, biological markers, and clinical features. Methods: Data from 1695 lymphoma cases were analyzed: 1137 (67.08%) from the NCI, 343 (20.24%) from other Ukrainian regions, and 215 (12.68%) from Romania. Comparative statistical analysis of disease subtypes, staging, biological markers, and clinical features was conducted using ANOVA and the Kruskal‐Wallis H‐test. Results: Mature B‐cell neoplasms constituted the majority of cases (71.21%), with significant differences across cohorts. Chronic lymphocytic leukemia (CLL) was more prevalent in non‐NCI Ukrainian regions (22.16%) and Romania (21.40%) compared to the NCI (7.48%) (p < 0.005), reflecting regional differences in referral patterns. Diffuse large B‐cell lymphoma (DLBCL) represented 23.37% of cases overall, with a higher proportion in non‐NCI Ukrainian cases (26.24%) compared to NCI (22.93%) and Romania (20.93%). Primary mediastinal large B‐cell lymphoma (PMBCL) was significantly more common in the NCI cohort (10.5%) compared to non‐NCI Ukrainian cases (2.9%) and Romanian cases (2.4%) (p < 0.005), similarly, primary CNS lymphoma was observed exclusively in the NCI cohort (8.6%), with no cases reported from regional Ukrainian or Romanian registries, this discrepancy can be explained by the fact that NCI functions as a reference center, receiving patients from across Ukraine. Advanced‐stage disease (Stage III‐IV) was more prevalent in non‐NCI Ukrainian cases (71.14%) than in Romanian (55.35%) and NCI patients (55.45%) (p < 0.005). Bone marrow involvement was detected in 13.22% of cases, with higher rates in non‐ NCI Ukrainian regions (16.62%) compared to NCI (12.66%) and Romanian cases (10.7%). Extranodal involvement was significantly more common at the NCI (49.34%) than in non‐NCI Ukrainian cases (37.32%) and Romanian cases (25.58%) (p< 0.005).
L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
(ООО «МОРИОН», 2017-12) Skrypnyk, I.; Maslova, G.; Lymanets, T.; Gusachenko, I.; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна; Лиманець, Тетяна Володимирівна
Quality of life evaluation in acute leukemia patients receiving induction chemotherapy
(European society for medical oncology, 2018-10) Lymanets, T. V.; Skrypnyk, I. M.; Maslova, G. S.; Gusachenko, I.; Лиманець, Тетяна Володимирівна; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна
Background: Over the past decades, special attention has been paid to study of quality of life (QoL) indicators in hematological patients receiving chemotherapy (CT). Nowadays QoL is conceptually viewed as an important complement to traditional objective evaluation measures. Aim. To assess QoL in patients with acute leukemia (AL) depending on the presence of concomitant ischemic heart disease (1HD) during the induction CT. Methods: Our study involved 83 patients with newly diagnosed AL, of which 19 were lymphoblastic, 64-myeloid leukemia, aged 16-72,43 (51.8%) men, 40 (48.2%) women, according to ECOG l-II. Patients received standard induction CT. According to concomitant IFID patients were divided into groups: I (n — 47) - AL without cardio logical diseases; II (n = 36) - AL with concomitant IHD. Patients were evaluated using SF-36 questionnaire to calculate physical and mental health components before treatment and after 2 induction courses of CT reaching remission.
Quality of life in acute leukemia patients with comorbid ischemic heart disease
(2018-06-14) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Gusachenko, I.; Скрипник, Ігор Миколайович; Лиманець, Тетяна Володимирівна; Маслова, Ганна Сергіївна
Regular physical activity improves quality of life of people with hemophilia: ukrainian single center studyin a real-life cohort
(Elsevier, 2025-06-22) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Gusachenko, I.; Лиманець, Тетяна Володимирівна; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна; Гусаченко, Юлія Олександрівна
Background: The introduction of the latest preventive schemes into hemophilia treatment protocols has reduced the percentage of disability and improved the quality of life of patients. Meanwhile, in Ukraine, as of 2022, 80-90% of children with hemophilia under the age of 14 became disabled, and almost 100% by the age of 21. In addition to medication, encouraging patients to engage in physical activity and sports plays an important role. Aims: To assess the impact of regular physical activity (PA) on the quality of life (QoL) of people with hemophilia. Methods: A survey of 51 people with hemophilia was conducted, which included an assessment of the frequency, regularity and type of PA, as well as the presence and extent of hemophilic arthropathies. They were divided into two groups: I (n=17) - Hemophilia A and B people with joint damage, aged 38,5±2,95 years, and II (n=34) - aged 11,6±0,44 without severe hemophilic arthropathy. Depending on the presence of regular PA, patients in both groups were divided into subgroups: IA (n=5) and IIA (n=23) - people with regular PA; IB (n=12) and IIB (n=11) - no reported PA. QoL was assessed using a EQ-5D- 5L questionnaire.
Risk assessment of anthracycline cardiotoxicity in patients with acute leukemia and concomitant ischemic heart disease
(Hemasphere journal, 2019) Lymanets, T. V.; Skrypnyk, I. M.; Maslova, H. S.; Gusachenko, I.; Лиманець, Тетяна Володимирівна; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна
Background: Great attention has recently been focused on the problem of chemotherapy (CT) complications in patients with acute leukemia (AL). Notable among them is the anthracycline cardiotoxicity (AC), the development of which greatly inhibits the carrying out of CT in full doses, which significantly reduces the patients’ chances for life. The presence of concomitant ischemic heart disease (IHD) potentiates the formation of AC, increases the risk of myocardial injury development. Aims: To assess the risk factors of AC development on low cumulative doses of anthracycline antibiotics (AA) and to increase the efficacy of AC prevention in patients with AI, taking into account concomitant IHD. Methods: The study involved 147 patients with newly diagnosed AL, 72 (49%) males and 75 (51%) females, mean age 54.7 ± 9.3 years, ECOG I-II. All patients were treated in hematology department of Poltava Regional Clinical Hospital n.a.M.V.Sklifosovsky. Depending on the IHD presence, the patients were divided into two groups: I (n = 81)-AL pts without concomitant cardiovascular diseases; II (n = 66)-AL pts with IHD. Due to ongoing AC prevention with L-arginine patients of both groups were further subdivided: IA (n = 47) and IIA (n = 36)—pts receiving CT; IB (n = 34) and IIB (n = 30)-pts, who received CT with prophylaxis of AC with L-arginine. The study was approved by the local ethical committee and all patients and all patients signed the inform consent before they were included. The examination was carried out twice: at baseline and after induction CT, when remission was achieved and AA low cumulative doses <200 mg/m2 were reached. The cardiotoxic effect of AA was evaluated by echocardiography and ITolter ECG monitoring and considered to be according to CTCAE 4.03 as reduction of left ventricular ejection fraction (l.VF.F) more than 10% of baseline and QTc prolongation exceeded 450ms. The episodes of “silent ischemia” were assessed on the basis of ST segment depression by 1 mm or more in the absence of typical pain syndrome.
The impact of forced internal displacement due to the full-scale russian invasion in Ukraine on the multiple myeloma (MM) patients’ survival and quality of life (QoL): the real-life observational study
(Elsevier, 2025-09) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Gusachenko, I.; Лиманець, Тетяна Володимирівна; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна; Гусаченко, Юлія Олександрівна
Context: The beginning of a full-scale invasion and active hostilities in Ukraine after February 24, 2022, caused mass displacement - citizens left their homes in search of safety and protection. Currently, the number of officially registered internally displaced persons (IDP) in Ukraine reaches 4.9 million people. This fact and newly diagnosed multiple myeloma (MM) may significantly influence a patient’s quality of life (QoL) and survival. Aim: The primary endpoint was to assess the overall survival (OS) of MM patients who were internally displaced from the territories of active hostilities to Poltava region. The second endpoint was to assess their QoL. Materials and Methods: Our study included 84 primary patients with MM during 2022–2023 after the full-scale Russian invasion of Ukraine. Median age, 64.6 ± 7.57 years; male, 46 (54.8%); female, 38 (45.2%); and ECOG 0–2. The patients were divided into two groups: Group 1 (N = 60), native citizens of the Poltava region, and Group 2 (N = 24), IDP from regions of active hostilities (Kharkiv, n = 11; Donetsk, n = 8; Sumy, n = 3; Luhansk, n = 2). The 2-year OS was assessed and QoL was evaluated by EQ- 5D-5L with descriptive data and visual analog scoring (EQ-VAS). Results: The 2-year OS was 56% in citizens native to the Poltava Region (Group 1) and 22% in IDP withMM(Group 2; hazard ratio [HR], 2.338; 95% CI, 1.17–4.68; P = 0.0162). There was no significant difference between patients in the two groups in impairments of mobility, self-care, and pain/discomfort data. The usual activities, such as work, study, housework, family or leisure activities, were significantly impaired in Group 2 patients compared to Group 1 (X2[1, N = 84] = 10.14, P < 0.04). Additionally, the results showed an increased level of anxiety/depression in patients of Group 2 who had moved to the Poltava region due to active hostilities (X2[1, N = 84] = 24.9, P = 0.000053). EQ-VAS data for Group 2 patients was significantly lower compared with Group 1 reported parameters (57.02 ± 9.88 vs 69.92 ± 7.86; P = 0.00001).

Перегляд за Автор "Gusachenko, I."

Результатів на сторінці

Налаштування сортування